18:14 , Jun 16, 2017 |  BioCentury  |  Emerging Company Profile

Metabolic regulation

ImmunoMet Therapeutics Inc. is developing a portfolio of biguanide derivatives that have the anticancer properties of metformin but are better optimized for the indication. Some starve drug-resistant cancers by blocking a metabolic pathway they rely...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Financial News

ImmunoMet completes venture financing

ImmunoMet Therapeutics , Houston, Texas   Business: Cancer   Date completed: 2016-03-08   Type: Venture financing   Raised: $5.2 million   Investors: Mirae Asset Venture Investment; Aju Tech; GNTech; MetaVest  ...
02:27 , Mar 9, 2016 |  BC Extra  |  Financial News

ImmunoMet raises $5.2M in series A

ImmunoMet Therapeutics (Houston, Texas) raised $5.2 million in a series A round led by Mirae Asset Venture Investments. Aju Tech, GNTech and MetaVest also participated. Next half, ImmunoMet expects to begin a Phase I study...